TMS benefits can last for months and, for many people who initially respond, through a year, but relapse remains possible, according to a systematic review and meta-analysis of durability. There is no guaranteed expiration date—or guaranteed lasting recovery—and long-term follow-up research shows that some patients receive additional TMS after their initial course.
The practical question is not simply how long the effect lasts. It is what staying well involves: monitoring symptoms, continuing appropriate depression care, and knowing how to seek reassessment if improvement starts to fade.
What does “lasting” mean after TMS?
This article concerns TMS for major depression, for which FDA-cleared devices and protocols are available. That does not mean every device, treatment schedule, or proposed use has FDA clearance. Off-label treatment is distinct from FDA-cleared treatment; ask your prescriber how your proposed plan fits the device’s labeling.
Several terms help make follow-up findings easier to understand:
- Response means a meaningful reduction in symptoms under a study’s definition. Someone can respond while still having depression symptoms.
- Remission means symptoms have fallen below a defined threshold. It is not a promise that depression will never return.
- Durability describes how well improvement persists after acute treatment.
- Relapse generally refers to a return or worsening of depression after improvement, although research definitions vary.
These distinctions matter. A finding about sustained response should not be presented as a finding that everyone remained symptom-free. Likewise, improvement maintained with additional care is different from improvement maintained without further treatment.
Initial improvement is not the same as long-term benefit
Before asking how long TMS lasts, it helps to separate the likelihood of initial improvement from the likelihood of keeping that improvement.
In the multisite acute outcomes study, researchers studied 307 outpatients at 42 US TMS practices. The reported clinical response rate was 58.0%, and the remission rate was 37.1%. Those are acute-treatment findings, not estimates of how many people stayed well afterward.
Durability research asks a different question: among people who improve, how much of that benefit remains later? A percentage calculated among initial responders cannot be applied to everyone starting TMS.
For someone exploring TMS for depression, both questions belong in the consultation. Discuss what would count as meaningful improvement for you and how the prescriber would assess whether that improvement continues.
What the year-long follow-up study found
The multisite durability study followed 257 patients for 52 weeks. Among initial responders or remitters, 62.5% still met response criteria through the year. The study also reported that 36.2% of patients needed reintroduction of TMS.
The encouraging point is that sustained improvement was possible. The equally important qualification is that the study describes outcomes in ongoing clinical care, not a guarantee that an acute course works indefinitely without additional treatment.
Interpret the findings carefully:
- The sustained-response figure concerns initial responders or remitters, not everyone beginning treatment.
- Continuing to meet response criteria does not necessarily mean remaining in remission or having no symptoms.
- Reintroduction of TMS is not necessarily the same as receiving a complete repeat acute course.
- The reintroduction figure should not be treated as the percentage who received scheduled preventive maintenance.
Because this was a naturalistic, observational study, it documents what happened in clinical practice. It does not establish that a particular follow-up schedule caused better durability or identify the best schedule for an individual patient.
Nor does the study’s follow-up endpoint establish an expiration date. It tells us about the period observed, rather than when an individual’s benefit must end.
What the durability meta-analysis adds
A systematic review and meta-analysis brings together findings across studies rather than relying on a single clinical sample.
The durability review by Senova and colleagues supports a balanced conclusion: benefits of an acute TMS course are generally maintained for months to a year in many responders, but relapse is common and maintenance or repeat treatment is often needed.
That supports neither “TMS wears off quickly for everyone” nor “a successful course permanently resolves depression.” Both statements flatten a variable course of illness into a promise the evidence cannot support.
The review’s broad conclusion also does not supply a personal forecast. Your prescriber still needs to consider your current symptoms, previous episodes, treatment history, and ongoing care when discussing follow-up.
How often do people need maintenance or another course?
There is no single percentage in these supplied sources that answers every version of this question. The clearest practice-based figure here is that 36.2% needed TMS reintroduction in the year-long follow-up study. That is useful context, not an individual probability or a universal maintenance rate.
Clinicians may use several related terms:
- Maintenance TMS: sessions scheduled after the acute course with the aim of sustaining improvement.
- Rescue or reintroduction treatment: additional sessions considered when symptoms begin returning.
- Repeat course: a renewed treatment series after reassessment of recurrent or worsening depression.
Terminology can vary between practices. Ask what a provider means rather than assuming “maintenance” and “repeat course” describe the same plan.
These terms do not establish FDA clearance. A proposed follow-up schedule may differ from a device’s FDA-cleared labeling; ask whether it is within that labeling or is off-label, and what evidence supports it.
The sources summarized here do not justify a universal maintenance interval. Decisions about whether additional sessions are appropriate—and how they would be scheduled—belong in a consultation with the treating prescriber.
Plan follow-up before the acute course ends
A follow-up plan can reduce uncertainty even when it cannot eliminate relapse risk. It should explain how improvement will be assessed and what happens if symptoms change.
Useful questions include:
- Who will oversee depression care after the TMS course?
- How will symptoms and day-to-day functioning be monitored?
- Which changes should prompt a call or earlier appointment?
- Who will reassess whether additional TMS or another approach is appropriate?
- If TMS is reintroduced, how will benefit be evaluated?
Discuss sleep, motivation, concentration, work, and relationships alongside symptom questionnaires. These details can help the prescriber understand whether recovery feels stable in everyday life.
Follow-up may also involve medication management or psychotherapy when clinically appropriate. Do not assume finishing TMS means other care should stop; medication changes should be discussed with the prescribing clinician.
Make the logistics part of the discussion
For New Jersey patients, access matters if reassessment or additional sessions become necessary. Someone traveling between Jersey City and a treatment office may face different practical constraints than someone receiving care close to home in Princeton.
Before committing, ask about appointment availability, workday scheduling, transportation, and how quickly the practice can arrange a reassessment. When comparing New Jersey TMS providers, include follow-up arrangements alongside the acute-treatment plan.
Financial planning deserves the same attention. Review insurance questions for TMS and ask your insurer and provider whether maintenance sessions or a repeat course require separate authorization. Do not assume approval for acute treatment automatically covers later sessions.
Ask for a clear explanation of potential out-of-pocket responsibility before agreeing to additional treatment. Coverage decisions and clinical recommendations are separate questions.
The takeaway
TMS durability is better understood as a follow-up question than a countdown. The research supports lasting benefit for many initial responders while also documenting the need for additional care in some patients, as described in the durability review.
A prescriber consultation can turn that uncertainty into a practical plan: define improvement, monitor it, clarify access and coverage, and decide how returning symptoms would be reassessed.
References
- Carpenter LL et al. Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depression and Anxiety, 2012. PMID 22689344
- Dunner DL et al. A multisite, naturalistic, observational study of TMS for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry, 2014. PMID 25271871
- Senova S et al. Durability of antidepressant response to repetitive transcranial magnetic stimulation: Systematic review and meta-analysis. Brain Stimulation, 2018. PMID 30344109